BioSpace News Archive

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.

Global “Protein Design and Engineering Market” in terms of revenue was estimated to be worth $5.47 Bn in 2023 and is poised to reach $14.69 Bn by 2031, growing at a CAGR of 13.39% from 2024 to 2031 according to a new report by InsightAce Analytic.

NextCure, Inc. (Nasdaq: NXTC) today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago.

Mural Oncology plc (Nasdaq: MURA) today announced an upcoming poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting taking place May 31-June 4 in Chicago.

Supernus Pharmaceuticals, Inc. announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual Meeting, taking place May 31 - June 4 in Chicago.

Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.

Erasca, Inc. announced the company will present one oral presentation and two poster presentations at the upcoming American Society of Clinical Oncology Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time.

Intra-Cellular Therapies, Inc. announced that it has completed the sale of an additional 1,027,397 shares of its common stock at a public offering price of $73.00 per share on April 24, 2024, pursuant to the full exercise of the option granted by Intra-Cellular Therapies to the underwriters in connection with its previously announced public offering of 6,849,316 shares of common stock, which closed on April 22, 2024.